BaroPace, Inc. Announced First Patient Enrolled in Non-Pharmacologic Hypertension and Heart Failure Treatment Trial

SAMMAMISH, Wash. — BaroPace Inc., a medical device company focused on the development of PressurePace™, a real-time physiologic control software and hardware to regulate cardiac pacemakers to treat resistant hypertension and heart failure with preserved ejection fraction (HFpEF), today announced that the first patient has been enrolled in the Company’sContinue Reading

BaroPace Receives Approval for First-in-Human Clinical Trial

SAMMAMISH, Wash. — BaroPace, Inc., a medical technology company dedicated to using blood pressure to regulate pacemakers for patients with heart failure with preserved ejection fraction and hypertension, announced today that it has received approval from the Central Drugs Standard Control Organisation (CDSCO) of India to conduct its clinical trialContinue Reading